

SCIENTIFIC AND SOCIAL PROGRAMME

SUNDAY, 28 AUGUST 2011

6.00 – 7.30 pm *REGISTRATION AND OPENING RECEPTION - CAMELOT ROOM,
THE CHATEAU ON THE PARK*

MONDAY, 29 AUGUST 2011

8:00 - 9:00 am *REGISTRATION*

9:00 am Welcome and Announcements

1. ASCEPT PLENARY/SESSION 1

CHAIR: EVAN BEGG

9:05 am 1.1 **PLENARY SPEAKER**

Prof Carl MJ Kirkpatrick, Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia

Taking the piss in the critically ill: when $1+1 \neq 2$

10:00 am 1.2 *Paul Chin, Christchurch Hospital, Christchurch*

The performance of eGFR formulae for estimating gentamicin clearance

10.20 am 1.3 *Lisa Stamp, University of Otago, Christchurch*

Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dose of allopurinol

10.40 am *Morning Tea*

2. ASCEPT SESSION 2

CHAIR: JANE VELLA-BRINCAT

- 11:15 am 2.1 *Dan Wright, University of Otago, Dunedin*
A population pharmacokinetic model for allopurinol in gout patients
- 11:30 am 2.2* *Julia Korell, University of Otago, Dunedin*
Development and application of a pharmacokinetic model for the glycation of albumin
- 11:45 am 2.3 *Hesham Al-Sallami, University of Otago, Dunedin*
Estimating Fat Free Mass in Children
- 12:00 noon 2.4* *Claire Johnston, Royal North Shore Hospital, NSW, Australia*
Population Pharmacokinetics of Gentamicin in Older People: The Impact of Frailty
- 12:15 pm 2.5 *Evan Begg, University of Otago, Christchurch*
Extended-interval gentamicin dosing in adult patients with impaired renal function – should the dose interval be extended further?
- 12:30 pm *Lunch*

3. ASCEPT SESSION 3

CHAIR: BERIT JENSEN

- 1:30 pm 3.1 *Nick Holford, University of Auckland, Auckland*
Demonstration of symptomatic and disease modifying effects of levodopa in Parkinson's disease using the ELLDOPA study
- 1:45 pm 3.2 *Mark McKeage, University of Auckland, Auckland*
Mass balance, metabolism and excretion of [14C]ASA404 in cancer patients
- 2:00 pm 3.3 *Andrew McKean, Hillmorton Hospital, Christchurch*
Is it NICE to monitor lithium routinely?
- 2:15 pm 3.4 *Ganeesan Kichenadasse, Flinders Medical Centre, Adelaide, South Australia*
In silico assessment of erlotinib as a potential inhibitor of CYP3A-mediated drug clearance
- 2:30 pm 3.5 *Paul Zufferey, University of Otago, Dunedin*
Fondaparinux: not so simple renal elimination

* For consideration for student prize

2.45 pm *Afternoon Tea*

4. ASCEPT SESSION 4

CHAIR: PAUL CHIN

- 3.15 pm 4.1 *Steve Duffull, University of Otago, Dunedin*
The current funding model leaves pharmacists caught in the struggle between justice and non-maleficence
- 3:30 pm 4.2* *Ernieda Hatah, University of Otago, Dunedin*
General practitioners' perceptions of pharmacist prescribing in New Zealand
- 3.45 pm 4.3 *Jane Vella-Brincat, Christchurch Hospital, Christchurch*
The pharmacokinetics of the antiemetic cyclizine, and how it feels to be subjected to blood sample orientated research, in palliative care
- 4:00 pm 4.4 *Melanie Gamble, Christchurch Hospital, Christchurch*
An audit of adult acute epiglottitis antimicrobial guidelines
- 4.15 pm 4.5 *Pamela Buffery, Christchurch Hospital, Christchurch*
A retrospective pharmacokinetic review of the busulphan monitoring service at Christchurch Hospital

4:30 pm **ASCEPT AGM**

7.00 pm **CONFERENCE DINNER IN THE CAMELOT ROOM,
THE CHATEAU ON THE PARK**

* For consideration for student prize

TUESDAY, 30 AUGUST 2011



ASCEPT/7TH ANNUAL CARNEY PHARMACOGENOMICS SYMPOSIUM

8:30 – 9:00 am **CARNEY REGISTRATION**

9:00 am Welcome and Announcements

5. ASCEPT SESSION 5

CHAIR: CARL KIRKPATRICK

- 9.05 am 5.1* *Christine Dixon, The University of Queensland, Queensland, Australia*
A high-throughput screen for novel drugs acting on the $\alpha 2\beta 2\gamma 1$ GABA_A Receptor
- 9.20 am 5.2* *Matthew Bull, University of Auckland, Auckland*
Development of perforin inhibitors as pharmacological agents
- 9.35 am 5.3* *Nancy Jong, University of Auckland, Auckland*
Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in over-expressing HEK293 cells and rat dorsal root ganglion neurons
- 9.50 am 5.4* *FeiFei Feng, University of Otago, Dunedin*
Ketotifen uptake by rat brain endothelial (RBE4) cells is stereoselective
- 10.05 am 5.5* *Sarah Bushby, University of Otago, Dunedin*
Forensic investigations of a psychotropic drug using maggots in a brain model
- 10.20 am 5.6* *Chakradhar Lagishetty, University of Otago, Dunedin*
Biomarkers of aging to predict drug clearance in the elderly - a pilot study
- 10:35 am *Morning Tea*

* For consideration for student prize

6. CARNEY PLENARY/SESSION 1

CHAIR: MARTIN KENNEDY

- 11.05 am 6.1 *Prof Elizabeth J Phillips, Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia*
Translating pharmacogenetics into the clinic
- 12.00 pm 6.2 *Richard Gearry, University of Otago, Christchurch*
GWAS- an ignorant approach to genetics?
- 12.20 pm 6.3 *Berit Jensen, University of Otago, Christchurch*
LC-MS in clinical pharmacology and toxicology – from niche projects to routine screening
- 12.40 pm **PRESENTATION OF FRED FASTIER TRUST STUDENT PRIZE**
- 12.45 pm *Lunch*

7. CARNEY SESSION 2

CHAIR: REBECCA ROBERTS

- 1:45 pm 7.1 *Hannah Kennedy, Christchurch Hospital, Christchurch*
Identification of multiple sclerosis patients who are non-responsive to therapeutic IFN β : an assay to allow more informed treatment options.
- 2.00 pm 7.2 *Mei Zhang, University of Otago, Christchurch*
Determination of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in human red blood cells by LC-MS/MS
- 2.15 pm 7.3 *Nuala Helsby, University of Auckland, Auckland*
CYP2C19 poor metabolisers: who and why?
- 2.30 pm 7.4 *Murray Barclay, University of Otago, Christchurch*
High TMPT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment
- 2.45 pm *Afternoon Tea*

8. CARNEY SESSION 3

CHAIR: MURRAY BARCLAY

- 3.15 pm 8.1 *Janet Coller, University of Adelaide, Adelaide, Australia*
Association between immune genetic markers and alcohol dependence
- 3.35 pm 8.2 *Rebecca Roberts, University of Otago, Dunedin*
The benzbromarone story - is CYP2C9 genotype relevant to prescribing?
- 3.55 pm 8.3 *Patrick Gladding, University of Auckland, Auckland*
Personalised thienopyridine therapy: the cost effectiveness of genetic testing for CYP2C19 variants to guide treatment in patients with acute coronary syndromes
- 4.15 pm **CLOSING STATEMENT AND SESSION CLOSED**